Heparin blunts endotoxin-induced coagulation activation

Circulation

Volumn 100, Issue 25, 1999, Pages 2485-2490

  Pernerstorfer, Thomas ^b   Hollenstein, U ^c   Hansen, J B ^a   Knechtelsdorfer, M ^c   Stohlawetz, P ^c   Graninger, W ^c   Eichler, H G ^c   Speiser, W ^c   Jilma, B ^c  

^a UNIVERSITY OF TROMSØ   (Norway)

^b UNIVERSITY OF VIENNA   (Austria)

^c NONE

Author keywords

Anticoagulants; Coagulation; Endotoxin; Fibrin; Heparin

Indexed keywords

ANTITHROMBIN III; BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 7A; D DIMER; DALTEPARIN; ENDOTOXIN; FIBRIN DEGRADATION PRODUCT; HEPARIN; LIPOPOLYSACCHARIDE; LOW MOLECULAR WEIGHT HEPARIN; PLACEBO; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTHROMBIN; THROMBIN; THROMBOPLASTIN; TISSUE FACTOR PATHWAY INHIBITOR; TISSUE PLASMINOGEN ACTIVATOR;

ADULT; ANTICOAGULANT THERAPY; ANTIGEN EXPRESSION; ARTICLE; BLOOD CLOTTING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISSEMINATED INTRAVASCULAR CLOTTING; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG POTENCY; ENDOTOXEMIA; HEPARINIZATION; HUMAN; HUMAN EXPERIMENT; INTRAVENOUS DRUG ADMINISTRATION; MALE; MONOCYTE; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEPSIS; THROMBIN TIME;

EID: 0033613544     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.100.25.2485     Document Type: Article

References (35)

1. Mammen EF. The haematological manifestations of sepsis. J Antimicrob Chemother. 1998;41(suppl A):17-24.
2. de Jonge E, Levi M, Stoutenbeek CP, van Deventer SJ. Current drug treatment strategies for disseminated intravascular coagulation. Drugs. 1998;55:767-777.
3. Moore KL, Andreoli SP, Esmon NL, Esmon CT, Bang NU. Endotoxin enhances tissue factor and suppresses thrombomodulin expression of human vascular endothelium in vitro. J Clin Invest. 1987;79:124-130.
4. Rivers RP, Hathaway WE, Weston WL. The endotoxin-induced coagulant activity of human monocytes. Br J Haematol. 1975;30: 311-316.
5. Neumann FJ, Ott I, Marx N, Luther T, Kenngott S, Gawaz M, Kotzsch M, Schomig A. Effect of human recombinant interleukin-6 and interleukin-8 on monocyte procoagulant activity. ArteriosclerThromb Vasc Biol. 1997; 17:3399-3405.
6. Taylor FB Jr, Chang A, Ruf W, Morrissey JH, Hinshaw L, Catlett R, Blick K, Edgington TS. Lethal E. coli septic shock is prevented by blocking tissue factor with monoclonal antibody. Circ Shock. 1991;33: 127-134.
7. Levi M, van der Poll T, ten Cate H, van Deventer SJ. The cytokine-mediated imbalance between coagulant and anticoagulant mechanisms in sepsis and endotoxaemia. Eur J Clin Invest. 1997;27:3-9.
8. Mesters RM, Mannucci PM, Coppola R, Keller T, Ostermann H, Kienast J. Factor VIIa and antithrombin III activity during severe sepsis and septic shock in neutropenic patients. Blood. 1996;88:881-886.
9. Shimura M, Wada H, Wakita Y, Nakase T, Hiyoyama K, Nagaya S, Mon Y, Shiku H. Plasma tissue factor and tissue factor pathway inhibitor levels in patients with disseminated intravascular coagulation. Am J Hematol. 1997;55:169-174.
10. Bredbacka S, Blomback M, Wiman B, Pelzer H. Laboratory methods for detecting disseminated intravascular coagulation (DIC): new aspects. Acta Anaesthesiol Scand. 1993;37:125-130.
11. Sandset PM, Abildgaard U, Larsen ML. Heparin induces release of extrinsic coagulation pathway inhibitor (EPI). Thromb Res. 1988;50: 803-813.
12. Hansen JB, Sandset PM, Huseby KR, Huseby NE, Bendz B, Ostergaard P, Nordoy A. Differential effect of unfractionated heparin and low molecular weight heparin on intravascular tissue factor pathway inhibitor: evidence for a difference in antithrombotic action. Br J Haematol. 1998; 101:638-646.
13. Creasey AA, Chang AC, Feigen L, Wun TC, Taylor FB Jr, Hinshaw LB. Tissue factor pathway inhibitor reduces mortality from Escherichia coli septic shock. J Clin Invest. 1993;91:2850-2856.
14. Martich GD, Boujoukos AJ, Suffredini AF. Response of man to endotoxin. Immunobiology. 1993;187:403-416.
15. Jilma B, Blann A, Pernerstorfer T, Stohlawetz P, Eichler HG, Vondrovec B, Amiral J, Richter V, Wagner OF. Regulation of adhesion molecules during human endotoxemia: no acute effects of aspirin. Am J Respir Crit Care Med. 1999;159:857-863.
16. Anastassiades E, Lane DA, Ireland H, Flynn A, Curtis JR. A low molecular weight heparin ("fragmin") for routine hemodialysis: a crossover trial comparing three dose regimens with a standard regimen of commercial unfractionated heparin. Clin Nephrol. 1989;32:290-296.
17. Jilma B, Voltmann J, Albinni S, Stohlawetz P, Schwarzinger I, Gleiter CH, Rauch A, Eichler HG, Wagner OF. Dexamethasone down-regulates the expression of L-selectin on the surface of neutrophils and lymphocytes in humans. Clin Pharmacol Ther. 1997;62:562-568.
18. Pernerstorfer T, Stohlawetz P, Hollenstein U, Dzirlo L, Eichler H-G, Kapiotis S, Jilma B, Speiser W. Endotoxin-induced activation of the coagulation cascade in humans: effect of acetylsalicylic acid and acetaminophen. Arterioscler Thromb Vasc Biol. 1999;19:2517-2523.
19. Sandset PM, Larsen ML, Abildgaard U, Lindahl AK, Odegaard OR. Chromogenic substrate assay of extrinsic pathway inhibitor (EPI): levels in the normal population and relation to cholesterol. Blood Coagul Fibrinolysis. 1991;2:425-433.
20. Kapiotis S, Jilma B, Quehenberger P, Ruzicka K, Handler S, Speiser W. Morning hypercoagulability and hypofibrinolysis: diurnal variations in circulating activated factor VII, prothrombin fragment F1+2, and plasmin-plasmin inhibitor complex. Circulation. 1997;96:19-21.
21. Stohlawetz P, Kapiotis S, Seidl D, Hergovich N, Zellner M, Eichler HG, Stiegler G, Leitner G, Hocker P, Jilma B. Safety issues of plateletpheresis: comparison of the effects of two cell separators on the activation of coagulation, fibrinolysis, and neutrophils and on the formation of neutrophil-platelet aggregates. Transfusion. 1999;39:420-427.
22. Wiman B, Ranby M. Determination of soluble fibrin in plasma by a rapid and quantitative spectrophotometric assay. Thromb Haemost. 1986;55: 189-193.
23. Gargan PE, Gaffney PJ, Pleasants JR, Ploplis VA. A monoclonal antibody which recognizes an epitopic region unique to the intact fibrin polymeric structure. Fibrinolysis. 1993;7:275-283.
24. Levi M, ten Cate H, Bauer KA, van der Poll T, Edgington TS, Buller HR, van Deventer SJ, Hack CE, ten Cate JW, Rosenberg RD. Inhibition of endotoxin-induced activation of coagulation and fibrinolysis by pentoxifylline or by a monoclonal anti-tissue factor antibody in chimpanzees. J Clin Invest. 1994;93:114-120.
25. van der Poll T, Coyle SM, Levi M, Jansen PM, Dentener M, Barbosa K, Buurman WA, Hack CE, ten Cate JW, Agosti JM, Lowry SF. Effect of a recombinant dimeric tumor necrosis factor receptor on inflammatory responses to intravenous endotoxin in normal humans. Blood. 1997;89:3727-3734.
26. Osterud B, Flaegstad T. Increased tissue thromboplastin activity in monocytes of patients with meningococcal infection: related to an unfavourable prognosis. Thromb Haemost. 1983;49:5-7.
27. Pepe G, Giusti B, Attanasio M, Gori AM, Comeglio P, Martini F, Gensini G, Abbate R, Neri Serneri GG. Tissue factor and plasminogen activator inhibitor type 2 expression in human stimulated monocytes is inhibited by heparin. Semin Thromb Hemost. 1997;23:135-141.
28. Gori AM, Pepe G, Attanasio M, Falciani M, Abbate R, Prisco D, Fedi S, Giusti B, Brunelli T, Comeglio P, Gensini GF, Neri Serneri GG. Tissue factor reduction and tissue factor pathway inhibitor release after heparin administration. Thromb Haemost. 1999;81:598-593.
29. Pernerstorfer T, Jilma B, Eichler H-G, Aull S, Handler S, Speiser W. Heparin lowers plasma levels of activated factor VII. Br J Haematol. 1999;105:1127-1129.
30. Schulman S, Bech Jensen M, Varon D, Keller N, Gitel S, Horoszowski H, Heim M, Martinowitz U. Feasibility of using recombinant factor VIIa in continuous infusion. Thromb Haemost. 1996;75:432-436.
31. Kyrle PA, Brockmeier J, Weltermann A, Eichinger S, Speiser W, Lechner K, Eichler HG. Inhibition rather than enhancement of hemostatic system activation during initiation of oral anticoagulant treatment. Thromb Haemost. 1997;77:685-689.
32. Schrader J, Stibbe W, Armstrong VW, Kandt M, Muche R, Kostering H, Seidel D, Scheler F. Comparison of low molecular weight heparin to standard heparin in hemodialysis/hemofiltration. Kidney Int. 1988;33: 890-896.
33. Wieding JU, Hosius C. Determination of soluble fibrin: a comparison of four different methods. Thromb Res. 1992;65:745-756.
34. Dempfle CE, Pfitzner SA, Dollman M, Huck K, Stehle G, Heene DL. Comparison of immunological and functional assays for measurement of soluble fibrin. Thromb Haemost. 1995;74:673-679.
35. Suffredini AF, Harpel PC, Parrillo JE. Promotion and subsequent inhibition of plasminogen activation after administration of intravenous endotoxin to normal subjects. N Engl J Med. 1989;320:1165-1172.